Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia-Reference-Cited by-同舟云学术

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia

Published:2022-08-09 Issue:6 Volume:6 Page:837-846
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Gil Fabio^ORCID,Juliao-Baños Fabian^ORCID,Amador Luisa,Castano Natalia^ORCID,Reyes Juan Manuel^ORCID

Funder

Pfizer S.A.S

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-022-00360-4.pdf

Reference60 articles.

1. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7(1):113–20. https://pubmed.ncbi.nlm.nih.gov/25075198/

2. Cosnes J, Gowerrousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-1794.e4.

3. Danese S, Allez M, Van Bodegraven AA, et al. Small and large bowel: systematic review and meta-analysis unmet medical needs in ulcerative colitis: an expert group consensus. 2016 https://www.karger.com/ddi. Accessed 10 Sep 2021.

4. Cottone M, Scimeca D, Mocciaro F, et al. Clinical course of ulcerative colitis. Dig Liver Dis. 2008;40(Suppl 2):S247–52.

5. Juliao F, Calixto O. Prevalencia de enfermedad de crohn y colitis ulcerativa en poblacion adulta en colombia: analisis del sistema integral de informacion de proteccion social (SISPRO). acadi2017.gastrocol.com. 2017. http://acadi2017.gastrocol.com/abstract_app/Premio_mejor_poster_ACADI_2017/107_poster_final_acadi_17_prevalencia_eii_identificado.pdf. Accessed 9 Sep 2021.